News | September 16, 2024
Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana
Total investment incurred for setting up the new R&D Rs 250 crore
Total investment incurred for setting up the new R&D Rs 250 crore
Expect the international business including CDMO business to pick-up in the second half of the financial year
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated
